Clinical relevance of low-density Plasmodium falciparum parasitemia in untreated febrile children: A cohort study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 02 2020
accepted: 13 08 2020
entrez: 21 9 2020
pubmed: 22 9 2020
medline: 21 10 2020
Statut: epublish

Résumé

Low-density (LD) Plasmodium infections are missed by standard malaria rapid diagnostic tests (standard mRDT) when the blood antigen concentration is below the detection threshold. The clinical impact of these LD infections is unknown. This study investigates the clinical presentation and outcome of untreated febrile children with LD infections attending primary care facilities in a moderately endemic area of Tanzania. This cohort study includes 2,801 febrile pediatric outpatients (median age 13.5 months [range 2-59], female:male ratio 0.8:1.0) recruited in Dar es Salaam, Tanzania between 01 December 2014 and 28 February 2016. Treatment decisions were guided by a clinical decision support algorithm run on a mobile app, which also collected clinical data. Only standard mRDT+ cases received antimalarials. Outcomes (clinical failure, secondary hospitalization, and death) were collected in follow-up visits or interviews on days 3, 7, and 28. After patient recruitment had ended, frozen blood from all 2,801 patients was tested for Plasmodium falciparum (Pf) by ultrasensitive-quantitative polymerase chain reaction (qPCR), standard mRDT, and "ultrasensitive" mRDT. As the latter did not improve sensitivity beyond standard mRDT, it is hereafter excluded. Clinical features and outcomes in LD patients (standard mRDT-/ultrasensitive-qPCR+, not given antimalarials) were compared with those with no detectable (ND) parasitemia (standard mRDT-/ultrasensitive-qPCR-) or high-density (HD) infections (standard mRDT+/ultrasensitive-qPCR+, antimalarial-treated). Pf positivity rate was 7.1% (n = 199/2,801) and 9.8% (n = 274/2,801) by standard mRDT and ultrasensitive qPCR, respectively. Thus, 28.0% (n = 76/274) of ultrasensitive qPCR+ cases were not detected by standard mRDT and labeled "LD". LD patients were, on average, 10.6 months younger than those with HD infections (95% CI 7.0-14.3 months, p < 0.001). Compared with ND, LD patients more frequently had the diagnosis of undifferentiated fever of presumed viral origin (risk ratio [RR] = 2.0, 95% CI 1.3-3.1, p = 0.003) and were more often suffering from severe malnutrition (RR = 3.2, 95% CI 1.1-7.5, p = 0.03). Despite not receiving antimalarials, outcomes for the LD group did not differ from ND regarding clinical failures (2.6% [n = 2/76] versus 4.0% [n = 101/2,527], RR = 0.7, 95% CI 0.2-3.5, p = 0.7) or secondary hospitalizations (2.6% [n = 2/76] versus 2.8% [n = 72/2,527], RR = 0.7,95% CI 0.2-3.2, p = 0.9), and no deaths were reported in any Pf-positive groups. HD patients experienced more secondary hospitalizations (10.1% [n = 20/198], RR = 0.3, 95% CI 0.1-1.0, p = 0.005) than LD patients. All the patients in this cohort were febrile children; thus, the association between parasitemia and fever cannot be investigated, nor can the conclusions be extrapolated to neonates and adults. During a 28-day follow-up period, we did not find evidence of a difference in negative outcomes between febrile children with untreated LD Pf parasitemia and those without Pf parasitemia. These findings suggest LD parasitemia may either be a self-resolving fever or an incidental finding in children with other infections, including those of viral origin. These findings do not support a clinical benefit nor additional risk (e.g. because of missed bacterial infections) to using ultrasensitive malaria diagnostics at a primary care level.

Sections du résumé

BACKGROUND
Low-density (LD) Plasmodium infections are missed by standard malaria rapid diagnostic tests (standard mRDT) when the blood antigen concentration is below the detection threshold. The clinical impact of these LD infections is unknown. This study investigates the clinical presentation and outcome of untreated febrile children with LD infections attending primary care facilities in a moderately endemic area of Tanzania.
METHODS/FINDINGS
This cohort study includes 2,801 febrile pediatric outpatients (median age 13.5 months [range 2-59], female:male ratio 0.8:1.0) recruited in Dar es Salaam, Tanzania between 01 December 2014 and 28 February 2016. Treatment decisions were guided by a clinical decision support algorithm run on a mobile app, which also collected clinical data. Only standard mRDT+ cases received antimalarials. Outcomes (clinical failure, secondary hospitalization, and death) were collected in follow-up visits or interviews on days 3, 7, and 28. After patient recruitment had ended, frozen blood from all 2,801 patients was tested for Plasmodium falciparum (Pf) by ultrasensitive-quantitative polymerase chain reaction (qPCR), standard mRDT, and "ultrasensitive" mRDT. As the latter did not improve sensitivity beyond standard mRDT, it is hereafter excluded. Clinical features and outcomes in LD patients (standard mRDT-/ultrasensitive-qPCR+, not given antimalarials) were compared with those with no detectable (ND) parasitemia (standard mRDT-/ultrasensitive-qPCR-) or high-density (HD) infections (standard mRDT+/ultrasensitive-qPCR+, antimalarial-treated). Pf positivity rate was 7.1% (n = 199/2,801) and 9.8% (n = 274/2,801) by standard mRDT and ultrasensitive qPCR, respectively. Thus, 28.0% (n = 76/274) of ultrasensitive qPCR+ cases were not detected by standard mRDT and labeled "LD". LD patients were, on average, 10.6 months younger than those with HD infections (95% CI 7.0-14.3 months, p < 0.001). Compared with ND, LD patients more frequently had the diagnosis of undifferentiated fever of presumed viral origin (risk ratio [RR] = 2.0, 95% CI 1.3-3.1, p = 0.003) and were more often suffering from severe malnutrition (RR = 3.2, 95% CI 1.1-7.5, p = 0.03). Despite not receiving antimalarials, outcomes for the LD group did not differ from ND regarding clinical failures (2.6% [n = 2/76] versus 4.0% [n = 101/2,527], RR = 0.7, 95% CI 0.2-3.5, p = 0.7) or secondary hospitalizations (2.6% [n = 2/76] versus 2.8% [n = 72/2,527], RR = 0.7,95% CI 0.2-3.2, p = 0.9), and no deaths were reported in any Pf-positive groups. HD patients experienced more secondary hospitalizations (10.1% [n = 20/198], RR = 0.3, 95% CI 0.1-1.0, p = 0.005) than LD patients. All the patients in this cohort were febrile children; thus, the association between parasitemia and fever cannot be investigated, nor can the conclusions be extrapolated to neonates and adults.
CONCLUSIONS
During a 28-day follow-up period, we did not find evidence of a difference in negative outcomes between febrile children with untreated LD Pf parasitemia and those without Pf parasitemia. These findings suggest LD parasitemia may either be a self-resolving fever or an incidental finding in children with other infections, including those of viral origin. These findings do not support a clinical benefit nor additional risk (e.g. because of missed bacterial infections) to using ultrasensitive malaria diagnostics at a primary care level.

Identifiants

pubmed: 32956354
doi: 10.1371/journal.pmed.1003318
pii: PMEDICINE-D-20-00426
pmc: PMC7505590
doi:

Substances chimiques

Antimalarials 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003318

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2235-40
pubmed: 26858424
PLoS Med. 2016 Jan 19;13(1):e1001942
pubmed: 26783752
Am J Trop Med Hyg. 2017 Nov;97(5):1540-1550
pubmed: 28820709
Malar J. 2010 Oct 13;9:282
pubmed: 20939931
Front Physiol. 2014 Nov 21;5:441
pubmed: 25484866
PLoS Med. 2017 Oct 23;14(10):e1002411
pubmed: 29059253
PLoS Med. 2009 Apr 28;6(4):e1000070
pubmed: 19399156
BMC Infect Dis. 2013 Nov 12;13:535
pubmed: 24215306
Blood. 2010 Jan 14;115(2):215-20
pubmed: 19901265
J Infect Dis. 2009 Nov 15;200(10):1509-17
pubmed: 19848588
Nat Rev Microbiol. 2014 Dec;12(12):833-40
pubmed: 25329408
Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):56-62
pubmed: 16931816
Malar J. 2011 Apr 29;10:107
pubmed: 21529365
Malar J. 2012 Nov 16;11:377
pubmed: 23158019
Clin Infect Dis. 2017 May 1;64(9):1221-1227
pubmed: 28369268
PLoS Med. 2015 Mar 03;12(3):e1001788
pubmed: 25734259
Parassitologia. 1999 Sep;41(1-3):247-50
pubmed: 10697863
Clin Microbiol Infect. 2018 Aug;24(8):845-855
pubmed: 29684634
Clin Infect Dis. 2010 Sep 1;51(5):506-11
pubmed: 20642354
J Infect Dis. 2019 Apr 16;219(9):1490-1498
pubmed: 30476111
PLoS One. 2015 Jul 10;10(7):e0132316
pubmed: 26161535
Lancet Infect Dis. 2018 Oct;18(10):1108-1116
pubmed: 30170986
Lancet Infect Dis. 2018 May;18(5):485-486
pubmed: 29398387
Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):479-82
pubmed: 1475809
Parasitology. 2016 Feb;143(2):129-38
pubmed: 26743626
Nat Commun. 2012;3:1237
pubmed: 23212366
PLoS One. 2012;7(9):e45542
pubmed: 23029082
PLoS One. 2011 Apr 12;6(4):e14798
pubmed: 21532754
Trop Med Int Health. 2010 Nov;15(11):1315-21
pubmed: 20958888
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
Clin Infect Dis. 2017 Oct 30;65(10):1769-1770
pubmed: 29020315

Auteurs

Mary-Anne Hartley (MA)

Centre for Primary Care and Public Health, University of Lausanne, Lausanne Switzerland.
EPFL, Machine Learning and Optimization Laboratory, Lausanne, Switzerland.

Natalie Hofmann (N)

Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.

Kristina Keitel (K)

Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.

Frank Kagoro (F)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.

Clara Antunes Moniz (C)

Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.

Tarsis Mlaganile (T)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.

Josephine Samaka (J)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Amana hospital, Dar es Salaam, United Republic of Tanzania.

John Masimba (J)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.

Zamzam Said (Z)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.

Hosiana Temba (H)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.

Iveth Gonzalez (I)

Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.

Ingrid Felger (I)

Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.

Blaise Genton (B)

Centre for Primary Care and Public Health, University of Lausanne, Lausanne Switzerland.
Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.

Valérie D'Acremont (V)

Centre for Primary Care and Public Health, University of Lausanne, Lausanne Switzerland.
Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH